ViiV last year I believe was looking for a partner for their unapproved once a week drug. They probably wanted to partner because there is not many once a week options and leronlimab looks strong in mono.. I believe they were willing to pay for the trials and this would have been for naive patents. This would be different in the combo for mdr2+ patients, where they optimize based on patient resistance. The advantages would be a partner like that would bring credibility and get some serious attention from biotech investors that normally don't invest in otc.

But I believe cydy will wait for mono results first, where the wild card is the FDA as we have seen with combo. It is nice knowing they have backup options, i.e. leronlimab will be more than just a drug for the mdr2+ population in HIV.